Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL ConsortiumLijuan Deng, Ken H. Young, Zijun Y. Xu‐Monette et al.|Leukemia|2015Cited by 83
Clinical and Biologic Significance of <i>MYC</i> Genetic Mutations in <i>De Novo</i> Diffuse Large B-cell LymphomaZijun Y. Xu‐Monette, Ken H. Young, Qipan Deng et al.|Clinical Cancer Research|2016Cited by 66
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphomaYi Xia, Ken H. Young, Zijun Y. Xu‐Monette et al.|Leukemia|2016Cited by 64
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOPZijun Y. Xu‐Monette, Ken H. Young, J. Han van Krieken et al.|Modern Pathology|2015Cited by 54
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapiesZijun Y. Xu‐Monette, Ken H. Young, Jianyong Li et al.|Journal for ImmunoTherapy of Cancer|2019Cited by 28